Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New tumor inhibitor for treatment of hereditary breast cancer shows promising results in mouse model

30.10.2008
Researchers of the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital used the novel inhibitor AZD2281 to target breast cancer, in which the BRCA1-gene plays a role, in a genetically engineered mouse model.

Treatment resulted in tumor regression and a strong increase in survival without signs of toxicity.

The inhibitor, which recently entered trials in human cancer patients, thus seems to have therapeutic potential for BRCA-defective tumors. Sven Rottenberg, Piet Borst and Jos Jonkers publish their results this week in PNAS Online Early Edition.

Resistance

Long-term treatment with AZD2281 in the mouse model did result in the development of drug resistance. This could however be reversed by coadministration of an other type of inhibitor, tariquidar. Furthermore, the researchers studied the effect of combined treatment with AZD2281 and cisplatin or carboplatin. This increased the recurrence-free and overall survival, suggesting that AZD2281 potentiates the effect of these DNA-damaging agents.

Model

The researchers previously developed the mouse model to study BRCA1-associated breast tumors. BRCA1 defects are often observed in so called triple-negative tumors. No targeted therapy exists yet for this type of breast cancer, which account for about 15% of all breast tumors. The researchers now use the mouse model for preclinical evaluation of potential therapeutics that target tumors with BRCA1 defects and that might be useful for treatment of triple-negative cancers.

The results with AZD2281 show that the mouse model is not only useful for the investigation of the efficacy and toxicity of chemical compounds. Also the development, prevention and circumvention of drug resistance can be tested in the model.

Hence, intervention studies in the mouse model may help to predict the basis of resistance to novel therapeutics well in advance of the human experience. Ultimately, this may improve the clinical success rate for novel anticancer drugs.

Frederique Melman | alfa
Further information:
http://www.nki.nl

More articles from Life Sciences:

nachricht Bolstering fat cells offers potential new leukemia treatment
17.10.2017 | McMaster University

nachricht Ocean atmosphere rife with microbes
17.10.2017 | King Abdullah University of Science & Technology (KAUST)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Ocean atmosphere rife with microbes

17.10.2017 | Life Sciences

Neutrons observe vitamin B6-dependent enzyme activity useful for drug development

17.10.2017 | Life Sciences

NASA finds newly formed tropical storm lan over open waters

17.10.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>